A Closer Look at Access to Essential Medicines in South Sudan

By HEOR Staff Writer

January 7, 2024

The Crucial Role of Medicines in Healthcare

When it comes to medical care and access to essential medicines in South Sudan, medicines are an essential component. Essential medicines play a crucial role in reducing morbidity and mortality rates from acute and chronic diseases. Meeting the United Nations’ Sustainable Development Goals (SDGs) requires comprehensive research and policy implementation to ensure easy access to these medicines. A global commitment is necessary to address gaps in healthcare access and pharmaceutical supply chains. This commitment will support the World Health Organization’s goal of achieving 80% availability by 2025. A human right is the right to have access to medications that are safe, effective, of high quality, and inexpensive. The reality, however, is very different from this ideal in many low- and middle-income countries (LMICs), where access to medicines is frequently hindered by issues such as a lack of availability and an unaffordable price.

The Status Quo in South Sudan

Despite its efforts to boost its healthcare system since gaining independence, South Sudan faces numerous issues. Protracted violence, poverty, inefficient pharmaceutical supply management, an inadequately skilled workforce, lack of infrastructure, and climate change effects impede progress. The country has set up the Emergency Medications Fund (EMF) to improve the provision of essential drugs and high-quality medical services. The South Sudan Ministry of Health and other organisations collaborated to develop this fund. But difficulties still exist, particularly with regard to gaining access to essential medicines in South Sudan.

Investigating Medicine Prices, Availability, and Affordability

Researchers conducted a study in Juba County, South Sudan, to determine the pricing, availability, and affordability of essential drugs. They aimed to gauge the progress of the nation in enhancing the accessibility and affordability of its medical facilities. The study revealed inadequate availability of pharmaceuticals across all investigated sectors. The public sector showed an average availability of only 50.4%. The study found only 0.07% of the examined drugs affordable, declaring the majority as unaffordable due to high pricing.

Perspectives on the Future and Recommendations

The findings of the study on access to essential medicines in South Sudan led to the formulation of a number of conclusions and suggestions. Among these are the implementation of regulations that regulate prices, particularly in the private sector, the enhancement of funds for the health sector, and the expansion of the availability of medicines in the public sector. These findings can serve as substantial evidence for policymakers to use when formulating policies that will limit prices, boost the supply of medicines and make them more affordable, strengthen the public health system, and reorganise the pharmaceutical sector in South Sudan.

Reference url

Recent Posts

Pfizer Trump Drug Prices: A Landmark Deal for Affordable Medications

By Rene Pretorius

October 1, 2025

Summary President Trump announced that Pfizer has agreed to lower drug prices. This is part of a broader initiative to reduce prescription drug costs in the United States, particularly f...
PhRMA’s Patient Access Investment: $500 Billion Commitment to Domestic Infrastructure and Care

By HEOR Staff Writer

September 30, 2025

Yesterday PhRMA announced steps to boosting patient access to treatments. The announcement showcases the U.S. biopharmaceutical industry’s initiative to enhance patient access and stimulate economic growth. The announcement outlines a remarkable $500 billion in new U.S. infrastructure spending. I...
Sanofi Insulin Savings: Your Comprehensive Guide for 2025

By HEOR Staff Writer

September 29, 2025

Are you searching for effective Sanofi insulin savings options to manage diabetes medication costs in 2025? The Sanofi Patient Connection Savings Registration program offers an efficient pathway for eligible patients to save on key insulin products—helping reduce out-of-pocket expenses and promot...